Close Menu

NEW YORK (GenomeWeb) – Elucigene Diagnostics, a Manchester, UK-based molecular test provider, will seek US Food and Drug Administration clearance next year for a cystic fibrosis screening assay specific to the American population.

CEO Mark Street-Docherty said that the multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

Computational biologist James Taylor has died, according to Johns Hopkins University.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.